McGuire Investment Group LLC Buys 674 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

McGuire Investment Group LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 2.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 31,754 shares of the medical research company’s stock after purchasing an additional 674 shares during the period. Thermo Fisher Scientific accounts for about 2.8% of McGuire Investment Group LLC’s investment portfolio, making the stock its 12th biggest holding. McGuire Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $16,855,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC boosted its stake in Thermo Fisher Scientific by 104,536.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after buying an additional 8,347,260 shares during the last quarter. Providence Capital Advisors LLC boosted its stake in Thermo Fisher Scientific by 61,754.7% during the first quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after buying an additional 5,832,730 shares during the last quarter. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $3,105,677,000. Osaic Holdings Inc. lifted its stake in shares of Thermo Fisher Scientific by 1,963.5% in the 2nd quarter. Osaic Holdings Inc. now owns 2,204,394 shares of the medical research company’s stock valued at $53,628,000 after purchasing an additional 2,097,565 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of Thermo Fisher Scientific by 17.7% in the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after purchasing an additional 1,764,312 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Insiders Place Their Bets

In other news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TMO shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective on the stock. HSBC initiated coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They set a “buy” rating and a $610.00 price objective on the stock. Finally, Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $599.00.

Get Our Latest Report on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 0.2 %

Shares of TMO stock opened at $583.09 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock’s fifty day moving average price is $562.41 and its 200 day moving average price is $519.25. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company has a market cap of $222.34 billion, a price-to-earnings ratio of 37.74, a price-to-earnings-growth ratio of 2.45 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the previous year, the business earned $5.40 EPS. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.